FMO3

Across TCGA pan-cancer cohorts, FMO3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FMO3 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FMO3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FMO3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where FMO3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.906	0.444	<.001	27	view →
HNSC	OS	Tertile	III,IV	0.803	0.993	.017	14	view →
CCRCC	DFS	Median	IV	0.220	0.781	.017	10	view →
UCEC	OS	Median	III,IV	0.484	1.000	.031	8	view →
PDAC	DFS	Quartile	III,IV	0.968	0.418	.004	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FMO3–LUAD (DFS)

Open the LUAD breakdown →